Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tenofovir Alafenamide Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Gilead Sciences | Tigermed
Deal Size : Inapplicable
Deal Type : Inapplicable
Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2022
Lead Product(s) : Tenofovir Alafenamide Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Gilead Sciences | Tigermed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Alafenamide Fumarate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : Tenofovir Alafenamide Fumarate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir Alafenamide Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TAF Switch Study in Hepatitis B Monoinfection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2016
Lead Product(s) : Tenofovir Alafenamide Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable